Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253: 22–28PubMed

Beecher HK (1955) The powerful placebo. JAMA 159 (17): 1602–1606

Benkert O, Maier W (1990) The necessity of placebo application in psychotropic drug trials. Pharmacopsychiat 23: 203–205

Benson K, Hartz AJ (2008) A comparison of observational studies and randomized, controlled trials. In: Pimple KD (Hrsg) Research ethics. Ashgate, Aldershot, S 213–221

Buchanan WW (2002) Placebo tribulations. Can Med Assoc J 167 (5): 456

Bundesministerium für Gesundheit (2011) Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). http://www.bfarm.de/DE/Home/home_node.html. Zugegriffen: 30.01.13

Carpenter WT, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS (2000) Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry 57 (6): 533–538PubMed

Carpenter WT Jr., Appelbaum PS, Levine RJ (2003) The declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in Schizophrenia. Am J Psychiatry 160: 356–362PubMed

Carpenter WT Jr., Schooler NR, Kane JM (1997) The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 54 (5) :401–407PubMed

Cartwright N (2011) A philosopher’s view of the long road from RCTs to effectiveness. The Lancet 377: 1400–1401

CIOMS (2002) International ethical guidelines for biomedical research involving human subjects (1982/2002) (CIOMS-02). http://www.cioms.ch/publications/layout_guide2002.pdf. Zugegriffen: 30.01.13

CIOMS (2009) International ethical guidelines for epidemiological studies. http://www.ufrgs.br/bioetica/cioms2008.pdf. Zugegriffen: 30.01.13

Coppen A, Bailey J (2000) Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 60 (2): 121–130PubMed

Curson DA, Hirsch SR, Platt SD, Bamber RW (1986) Does short term placebo treatment of chronic schizophrenia produce long term harm? Br Med J (Clin Res Ed) 293: 726–728

Czobor P, Volavka J (2004) Placebo-controlled phase 3-studies of antipsychotics in schizophrenics. World J Biol Psychiat 5: 14

Zulueta de P (2001) Randomised placebo-controlled trials and HIV-infected pregnant women in developing countries. Ethical imperialism or unethical exploitation? Bioethics 15 (4): 289–311PubMed

Deisenhammer EA, Hinterhuber H (2003) Plazebokontrollierte Antidepressiva-Studien. Überlegungen zur Frage der ethischen Beurteilung. Fortschr Neurol Psychiatr 71: 243–248PubMed

Deutscher Bundestag (2011) Bundesdatenschutzgesetz (BDSG) (1990/2009). http://www.gesetze-im-internet.de/bundesrecht/bdsg_1990/gesamt.pdf. Zugegriffen: 30.01.13

Deutscher Bundestag (2010) Sozialgesetzbuch (SGB), Fünftes Buch (V), Gesetzliche Krankenversicherung. Zuletzt geändert durch Art. 2 G v. 22.12.2010, I 2309. http://www.kzvb.de/index.php?eID=tx_nawsecuredl&u†=†0&file=fileadmin%2Fuser_upload%2FKZVB%2FRecht_und_Vertraege%2FBlaue_Vertragsmappe%2Fpdf%2F2011†%†2FA_I_SGB_V.pdf&hash=e1759e70c6e7b09b8d991c8872c5f3ec. Zugegriffen: 30.01.13

Deutscher Ethikrat (2004/2010) Humanbiobanken für die Forschung. http://www.ethikrat.org/dateien/pdf/stellungnahme-humanbiobanken-fuer-die-forschung.pdf. Zugegriffen: 30.01.13

Dinnerstein AJ, Haim J (1970) Modification of placebo effects by means of drugs. J Abnorm Sociol Psychol 75: 308–314

Djulbegovic B (2001) Placebo-controlled trials. Ann Intern Med 135 (1): 62–63PubMed

Editorial C (2002) The better-than-nothing idea: debating the use of placebo controls. CMAJ 166 (5): 573–573

Edwards S, Lilford R, Braunholtz D, Jackson J, Hewison J, Thornton J (1998) Ethical issues in the design and conduct of randomised clinical trials. Health Technol Ass 2: 1–132

Ellenberg SS, Temple R (2000) Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 133 (6): 464–470PubMed

EMA (2011) EMEA/CPMP position statement on the use of placebo in clinical trials with regard to the revised declaration of Helsinki. http://www.ahppi.org.uk/CMS/STORE//EU20Directive/EU_placebo_files/ATTACHMENTS/EMEAposition.pdf. Zugegriffen: 30.01.13

Emanuel EJ, Miller FG (2001) The ethics of placebo-controlled trials – a middle ground. N Engl J Med 345: 915–919PubMed

Europäische Union (2000) Charter of fundamental rights of the European Union (2000/C 364/01) (CFR-00) http://www.europarl.europa.eu/charter/pdf/text_en.pdf. Zugegriffen: 30.01.13

Europäische Union (1950) Convention for the protection of human rights and fundamental freedoms (ECHR-50) (ETS no 005, 1950 as amended). http://www.echr.coe.int/NR/rdonlyres/D5CC24A7-DC13-4318-B457-5C9014916D7A/0/Convention_ENG.pdf. Zugegriffen: 30.01.13

Europäische Union (1995) EU-Richtlinie 95/46/EG „Zum Schutz natürlicher Personen bei der Verarbeitung personenbezogener Daten und zum freien Datenverkehr“. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:DE:NOT. Zugegriffen: 30.01.13

Europarat (2005) Additional protocol to the convention on human rights and biomedicine, concerning biomedical research (No. 195) (2005) (AD-05). http://www.coe.int/t/dg3/healthbioethic/Activities/02_Biomedical_research_en/195%20Protocole%20recherche%20biomedicale%20e.pdf. Zugegriffen: 30.01.13

Europarat (1981) Convention for the protection of individuals with regard to automatic processing of personal data (No. 108) (1981) (CPI-APPD-81). http://conventions.coe.int/Treaty/en/Treaties/Html/108.htm. Zugegriffen: 30.01.13

Europarat (2006) European standards on confidentiality and privacy in healthcare among vulnerable patient populations. Zit. nach: McClelland R (2010) Confidentiality. In: Helmchen H, Sartorius N (Hrsg) Ethics in psychiatry. Springer, Dordrecht, S 162

Europarat (1997) Übereinkommen zum Schutz der Menschenrechte und der Menschenwürde im Hinblick auf die Anwendung von Biologie und Medizin: Übereinkommen über Menschenrechte und Biomedizin. http://conventions.coe.int/treaty/ger/treaties/html/164.htm. Zugegriffen: 30.01.13

Falk A, Dohmen T, Huffman D, Sunde U, Schupp J, Wagner GG (2011) Individual risk attitudes: measurement, determinants and behavioral consequences. JEEA: 3

FDA (2001) Guidance for industry: E 10 choice of control group and related issues in clinical trials. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129460.pdf. Zugegriffen: 30.01.13

Ferriman A (2001) World Medical Association clarifies rules on placebo controlled trials. BMJ 323: 825PubMed

Fleischhacker WW, Burns T (2002) Feasibility of placebo-controlled clinical trials of antipsychotic compounds in Europe. Psychopharmacology (Berl) 162 (1): 82–84

Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J (2003) Placebo or active control trials of antipsychotic drugs? Arch Gen Psychiatry 60: 458–464PubMed

Forster HP, Emanuel E, Grady C (2001) The 2000 revision of the declaration of Helsinki: a step forward or more confusion? The Lancet 358: 1449–1453

Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J (2010) Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 303: 47–53PubMed

Friedman LM, Furberg CD, DeMets DL (1999) Fundamentals of clinical trials. Springer, Heidelberg

Fritze J, Gastpar M, Möller HJ (2000) Relevanz von Plazebo zur Kontrolle von Fehlerquellen beim Wirksamkeitsnachweis. In: Maier W, Engel RR, Möller HJ (Hrsg) Methodik von Verlaufs- und Therapiestudien in Psychiatrie und Psychotherapie. Hogrefe, Göttingen, S 70–82